Top Markets
Coin of the day
Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc.

VRPX
株式のランク #42776
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical... Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$124.00
変化(1日)
0.00%
変化(1年)
-99.09%
US
取引 Virpax Pharmaceuticals, Inc. (VRPX)

カテゴリー

Virpax Pharmaceuticals, Inc.(VRPX)の利益
2026 時点の利益 TTM: 0
Virpax Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Virpax Pharmaceuticals, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益